Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783892 | 1.00 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL2062991 | 1.00 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3378213 | 0.90 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3570961 | 0.90 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3585273 | 0.90 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1162230 | 0.89 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL27604122 | 0.89 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL16339562 | 0.87 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL16339563 | 0.87 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL13422140 | 0.86 | CTSK (0.46) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374858-A2 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| EP-3630291-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215801-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
| WO-2016112088-A1 | ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-9238631-B2 | Radiolabeled amino acids for diagnostic imaging | PIRAMAL IMAGING SA (CH) | 2016-01-19 | — | — | US | disclosed |
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | PIRAMAL IMAGING SA (CH) | 2015-01-08 | — | — | US | disclosed |
| EP-2520556-A1 | Radiolabeled amino acids for diagnostic imaging | Bayer Pharma Aktiengesellschaft (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| CN-101541800-A | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer | CHROMA THERAPEUTICS LTD (GB) | 2009-09-23 | — | — | CN | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| CN-1326557-C | aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | JOLLA PHARMA (US) | 2007-07-18 | — | — | CN | disclosed |
| EP-1606283-A4 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1606283-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| CN-1225015-A | aPL immunoreactive peptides, conjugates thereof and methods of treatment of aPL antibody-mediated diseases | LAJOLLA PHARMACEUTICAL CO (US) | 1999-08-04 | — | — | CN | disclosed |
| CN-1192153-A | aPL immunoreactive peptides and conjugates thereof and methods of treating aPL antibody-mediated diseases | JOLLA PHARMA (US) | 1998-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | SLC1A5, SLC6A19, BCAT2 | CTSK 627/4885CTSS 809/4885MEN1 34/4885 |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | CTSK 1427/4885CTSS 2371/4885MEN1 727/4885 |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CDK1, AURKC, CSNK1G3 | CTSK 622/4885CTSS 798/4885MEN1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.